OpGen

OpGen Pre-Tax Margin

The Pre-Tax Profit Margin of OpGen (OPGN) as of Oct 31, 2026 is 80.91 %. In the previous year, Pre-Tax Profit Margin was 234.20 % — a change of -65.45% (lower).

Pre-Tax Margin

80.91 %

YoY

-65.45%

Last updated:

Pre-Tax Profit Margin of OpGen is 2025 80.91 % . Pre-Tax Profit Margin of OpGen was 2024 234.20 % . It decreases by -65.45% lower compared to the previous year.

The OpGen Pre-Tax Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Pre-Tax Margin
Date
Pre-Tax Margin
Jan 1, 2018
-453.77 USD
Jan 1, 2019
-355.70 USD
Jan 1, 2020
-618.84 USD
Jan 1, 2021
-807.29 USD
Jan 1, 2022
-1,430.11 USD
Jan 1, 2023
-955.79 USD
Jan 1, 2024
234.20 USD
Jan 1, 2025
80.91 USD
The OpGen Pre-Tax Margin history
YEARPre-Tax MarginYoY
80.91 %-65.45%
234.20 %-124.50%
-955.79 %-33.17%
-1,430.11 %+77.15%
-807.29 %+30.45%
-618.84 %+73.98%
-355.70 %-21.61%
-453.77 %-5.34%
-479.38 %+0.69%
-476.11 %-13.99%
-553.55 %+302.74%
-137.45 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

OpGen Stock analysis

What does OpGen do? OpGen, Inc. generates revenue through its Acuitas-branded high-resolution DNA tests and bioinformatics solutions, targeting healthcare providers and hospitals globally. The company's molecular diagnostics and informatics products help combat infectious diseases by providing precise diagnostic information on life-threatening infections and multidrug-resistant microorganisms. These solutions guide clinicians in managing patient outcomes and hospital biome protection through customized screening and surveillance. The firm's DNA tests and bioinformatics address antibiotic resistance, offering data-driven insights for healthcare decision-making. The company's Acuitas trade name is used for its high-resolution DNA tests, which are marketed to healthcare settings focused on infectious disease management. OpGen's products help hospitals manage patient care decisions and protect against the spread of infections caused by multidrug-resistant pathogens. The firm's global network of customers and partners includes healthcare providers seeking to implement pathogen surveillance systems for improved infection control. OpGen's business model centers on delivering molecular information solutions that combine DNA testing with bioinformatics, creating a comprehensive approach to infectious disease management. The company's focus on antibiotic resistance and multidrug-resistant microorganisms drives demand for its Acuitas products, which are positioned as tools for guiding clinical decisions and optimizing hospital infection control protocols. OpGen is one of the most popular companies on Eulerpool.

Frequently Asked Questions about OpGen stock

Pre-Tax Profit Margin of OpGen is 80.91 % in 2025.

Pre-Tax Profit Margin of OpGen changed from 234.20 % to 80.91 %, representing a -65.45% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Pre-Tax Profit Margin OpGen since 2006 – with annual values, charts, and detailed analysis.

Pre-tax margin measures the percentage of revenue remaining after all expenses except income taxes. It isolates operational and financial performance from tax effects.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Pre-Tax Profit Margin's OpGen with sector peers and the industry average to assess whether it is attractive.

To evaluate Pre-Tax Profit Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Pre-Tax Profit Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — OpGen

All Key Metrics — OpGen